(1) Although kidney cancer is not in the top 10 of malignant tumor incidence, the incidence rate is increasing year by year, increasing by 1.6% to 3.8% in the past 10 years; (2) The overall prognosis is still good, with a 5-year survival rate close to 92% after surgery in the limited stage, about 12% at 5 years in the progressive stage, and about 1/3 are in the progressive stage at the time of initial diagnosis; (3) Pathological types: 80% are clear cell carcinoma, others are papillary carcinoma, suspicious cell carcinoma The median age at diagnosis is about 60 years; 4) Recurrence ratio and time: 20-30% of recurrence will occur after surgery, mostly within 3 years after surgery, and the most common time of recurrence and metastasis is 1-2 years after surgery. (5) The current research on postoperative adjuvant therapy for kidney cancer believes that neither interferon or interleukin cytokine therapy nor targeted therapy can bring about delayed recurrence and metastasis; (6) Advanced kidney cancer (metastasis or recurrence): mainly targeted therapy and cytokine therapy, the former has become more popular and respected in recent years. Kidney cancer is the frontier of targeted therapy as well as immunotherapy. Clinical studies on targeted drugs for kidney cancer have been in full swing in the past 8 years, and some of them have been approved for the market, such as sotan, sorafenib, pazopanib, axitinib, bevar, etc. The results of 184 are also very encouraging; and immunotherapy has also shown better results.